182 related articles for article (PubMed ID: 38565883)
1. Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade.
Nie H; Saini P; Miyamoto T; Liao L; Zielinski RJ; Liu H; Zhou W; Wang C; Murphy B; Towers M; Yang T; Qi Y; Kannan T; Kossenkov A; Tateno H; Claiborne DT; Zhang N; Abdel-Mohsen M; Zhang R
Nat Commun; 2024 Apr; 15(1):2853. PubMed ID: 38565883
[TBL] [Abstract][Full Text] [Related]
2. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
3. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
4. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
Gupta T; Vinayak S; Telli M
Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
Wan C; Keany MP; Dong H; Al-Alem LF; Pandya UM; Lazo S; Boehnke K; Lynch KN; Xu R; Zarrella DT; Gu S; Cejas P; Lim K; Long HW; Elias KM; Horowitz NS; Feltmate CM; Muto MG; Worley MJ; Berkowitz RS; Matulonis UA; Nucci MR; Crum CP; Rueda BR; Brown M; Liu XS; Hill SJ
Cancer Res; 2021 Jan; 81(1):158-173. PubMed ID: 33158814
[TBL] [Abstract][Full Text] [Related]
6. Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy.
Khatoon E; Parama D; Kumar A; Alqahtani MS; Abbas M; Girisa S; Sethi G; Kunnumakkara AB
Life Sci; 2022 Oct; 306():120827. PubMed ID: 35907493
[TBL] [Abstract][Full Text] [Related]
7. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
8. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
9. LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer.
Dey G; Bharti R; Braley C; Alluri R; Esakov E; Crean-Tate K; McCrae K; Joehlin-Price A; Rose PG; Lathia J; Gong Z; Reizes O
J Ovarian Res; 2023 Jun; 16(1):122. PubMed ID: 37370140
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers.
Alwosaibai K; Aalmri S; Mashhour M; Ghandorah S; Alshangiti A; Azam F; Selwi W; Gharaibeh L; Alatawi Y; Alruwaii Z; Alsaab HO
BMC Cancer; 2023 Jan; 23(1):13. PubMed ID: 36604635
[TBL] [Abstract][Full Text] [Related]
11. Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
Bruand M; Barras D; Mina M; Ghisoni E; Morotti M; Lanitis E; Fahr N; Desbuisson M; Grimm A; Zhang H; Chong C; Dagher J; Chee S; Tsianou T; Dorier J; Stevenson BJ; Iseli C; Ronet C; Bobisse S; Genolet R; Walton J; Bassani-Sternberg M; Kandalaft LE; Ren B; McNeish I; Swisher E; Harari A; Delorenzi M; Ciriello G; Irving M; Rusakiewicz S; Foukas PG; Martinon F; Dangaj Laniti D; Coukos G
Cell Rep; 2021 Jul; 36(3):109412. PubMed ID: 34289354
[TBL] [Abstract][Full Text] [Related]
12. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
[TBL] [Abstract][Full Text] [Related]
13. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
14. Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells.
Choi YE; Battelli C; Watson J; Liu J; Curtis J; Morse AN; Matulonis UA; Chowdhury D; Konstantinopoulos PA
Oncotarget; 2014 May; 5(9):2678-87. PubMed ID: 24798692
[TBL] [Abstract][Full Text] [Related]
15. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway.
Yanaihara N; Yoshino Y; Noguchi D; Tabata J; Takenaka M; Iida Y; Saito M; Yanagida S; Iwamoto M; Kiyokawa T; Chiba N; Okamoto A
Gynecol Oncol; 2023 Jan; 168():83-91. PubMed ID: 36403366
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers that may predict response to immunotherapy in ovarian malignancies.
Chin CD; Fares CM; Konecny GE; Rao J
Curr Opin Obstet Gynecol; 2020 Feb; 32(1):84-90. PubMed ID: 31804230
[TBL] [Abstract][Full Text] [Related]
18. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
19. STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8
Li A; Wang Y; Yu Z; Tan Z; He L; Fu S; Shi M; Du W; Luo L; Li Z; Liu J; Zhou Y; Fang W; Yang Y; Zhang L; Hong S
J Thorac Oncol; 2023 Dec; 18(12):1714-1730. PubMed ID: 37495171
[TBL] [Abstract][Full Text] [Related]
20. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
[No Abstract] [Full Text] [Related]
[Next] [New Search]